Skip to Main Content
  • Login
  • Contact Us
  • Donate

NANETS

  • About
    • Mission
    • Board of Directors
    • NANETS Structure
    • Staff
    • Committees
    • Committee Descriptions
    • NANETS Presidents
    • Lifetime Achievement
    • Outstanding Service
    • History
    • Diversity Statement
    • NANETS Awards
  • Education
    • NETCast Podcast Series
    • Regional NET Education
    • Virtual Programming Series
    • 2026 NET Medical Symposium
    • Conference Archives
    • About NETs
    • NANETS Call for Topics Calendar
  • Research
    • Abstracts Library
    • Abstract Instructions
    • Research Grants
    • Grant Recipients
  • Guidelines
  • Resources
    • Grant Resources
    • NANETS Mentorship Program
    • Employment Postings
    • Clinical Trials
    • Member DirectoryMember Directory
    • NET Around the World
    • Patient Resources
    • Women in NETs
    • COVID-19 Resource Page
    • NANETS Collaboration Submission Form
    • Provider Resources
  • News
    • NET eNews
    • Media
    • Endocrine-Related CancerEndocrine-Related Cancer
    • Photo Gallery
  • Membership
    • Member Login
    • Member Benefits
    • Member Categories
    • Join NOW
    • Spread the Word
    • Code of Conduct
  • 2025

  • 2024

  • 2023

  • 2022

  • 2021

  • 2020

  • 2019

  • 2018

  • 2017

  • 2016

  • 2015

  • 2014

  • 2013

  • 2012

  • 2011

  • 2010

  • 2009

[C8] Mosalem - Temozolomide Induced Hypermutation in Pancreatic Neuroendocrine Tumors: A Case Series

Published in 2024 Listed under Clinical

Download

[C8] Luo - Effect of Hepatic Impairment on Pharmacokinetics, Safety, and Tolerability of Oral Paltusotine, a Small- Molecule, Selective Somatostatin Receptor Subtype 2 Agonist

Published in 2023 Listed under Clinical

Download

[C8] Al-Toubah - Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-Differentiated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C7] Schnell - Cabozantinib therapy in patients with previously treated well differentiated grade 3 neuroendocrine tumors (G3 NETs)

Published in 2024 Listed under Clinical

Download

[C7] Poster - Schnell - Cabozantinib therapy in patients with previously treated well differentiated grade 3 neuroendocrine tumors (G3 NETs)

Published in 2024 Listed under Clinical, Poster

Download

[C7] Owen - A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms (NEN): Updated overall survival data

Published in 2023 Listed under Clinical

Download

[C7] Al-Toubah - Risk of Myelodysplastic Syndrome/Acute Leukemia with Sequential Capecitabine/Temozolomide and 177Lu-Dotatate

Published in 2022 Listed under Clinical

Download

[C6] Young - Evaluation of Switching SSAs on GI-NET Progression – Experience at an Academic Medical Center

Published in 2024 Listed under Clinical

Download

[C6] Poster - Young - Evaluation of Switching SSAs on GI - NET Progression: Experience at an Academic Medical Cente

Published in 2024 Listed under Clinical, Poster

Download

[C6] Kurian - The Role of Somatostatin Analogue Maintenance Therapy in Refractory Metastatic Neuroendocrine Tumors (NETs): Comparative Analysis

Published in 2023 Listed under Clinical

Download

[C6] Eads - An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C5] Jimenez - A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial

Published in 2023 Listed under Clinical

Download

[C5] Ghosh - c-MET Expression in MEN1-associated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C5] Chauhan - Once-daily Oral Paltusotine in the Treatment of Patients With Carcinoid Syndrome: Results From a Phase 2, Randomized, Parallel-Group Study

Published in 2024 Listed under Clinical

Download

[C59] Nigam - High Grade Medullary Thyroid Carcinoma Predicts Greater Lymph Node Burden in the Ipsilateral Lateral Neck

Published in 2023 Listed under Clinical

Download

[C58] Joseph - Do Pancreatic Well-differentiated Neuroendocrine Tumor (NET) Progress to Poorly-differentiated Neuroendocrine Carcinoma (NEC)?

Published in 2023 Listed under Clinical

Download

[C57] Hallet - Perioperative management of carcinoid crisis: protocol for a modified Delphi international expert consensus statement with patient engagement

Published in 2023 Listed under Clinical

Download

[C56] Laderian - Comparative gene expression and pathway analysis of neuroendocrine neoplasms in relation to clinical outcomes and tumor location

Published in 2023 Listed under Clinical

Download

[C55] Al-Toubah - Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Published in 2023 Listed under Clinical

Download

[C54] Ng - Tissue section thickness of Ki67 immunohistochemistry does not have a correlative effect on pancreatic neuroendocrine tumor grading

Published in 2023 Listed under Clinical

Download

[C52] AghaAmiri - Translational potential of a receptor-targeted contrast agent for fluorescence-guided applications in pancreatic neuroendocrine tumors

Published in 2023 Listed under Clinical

Download

[C51] Partelli - A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE Followed by Surgery for Pancreatic Neuroendocrine Tumors (NeoLuPaNET)

Published in 2023 Listed under Clinical

Download

[C50] Worthy - Phenotype Genotype Correlation in Multiple Endocrine Neoplasia Type 1

Published in 2023 Listed under Clinical

Download

[C4] Poster - Koch - Comparison of Survival Outcomes and Hypoglycemic Control in Patients Receiving Systemic Therapy for Malignant Insulinoma

Published in 2024 Listed under Clinical, Poster

Download

[C4] Mukherjee - Results from a Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/leucovorin in refractory advanced high-grade neuroendocrine cancer (HG-NEC)

Published in 2023 Listed under Clinical

Download

[C4] McLaughlin - Cisplatin vs Carboplatin in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas (PD NEC)

Published in 2022 Listed under Clinical

Download

[C4] Koch - Comparison of survival outcomes and hypoglycemic control in patients receiving systemic therapy for malignant insulinoma

Published in 2024 Listed under Clinical

Download

[C49] Su - National trends in surgical management of T1N0 well- differentiated pancreatic neuroendocrine tumors (PNET) and age-specific survival

Published in 2024 Listed under Clinical

Download

[C49] Poster - Su - National Trends in Surgical Management of T1N0 Well - Differentiated Pancreatic Neuroendocrine Tumors (PNET) and Age Specific Survival

Published in 2024 Listed under Clinical, Poster

Download

[C49] Meloche-Dumas - Post-procedure outcomes of liver-directed therapy of neuroendocrine liver metastases

Published in 2023 Listed under Clinical

Download

[C48] Wang - Predictors of low-to-high grade progression in pancreatic neuroendocrine tumors

Published in 2023 Listed under Clinical

Download

[C48] Poster - Collier - Impact of Hospital Type and Location on Survival Outcomes for Patients with Well - Differentiated Pancreatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical, Poster

Download

[C48] Collier - Impact of Hospital Type and Location on Survival Outcomes for Patients with Well-Differentiated G1/G2 Pancreatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical

Download

[C47] Slaby - Response After Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical

Download

[C47] Poster - Slaby - Response After Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical, Poster

Download

[C47] Fasih - Surgical Cytoreduction vs Systemic therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): NCDB Analysis.

Published in 2023 Listed under Clinical

Download

[C46] Dumitra - Clinical utility of preoperative DOTATATE-PET in small bowel neuroendocrine tumors

Published in 2024 Listed under Clinical

Download

[C46] Borbon - Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors

Published in 2023 Listed under Clinical

Download

[C45] Poster - Nkie - Interaction Between Race and Insurance Coverage for Gastroenteropancreatic Neuroendocrine Tumor Outcomes

Published in 2024 Listed under Clinical, Poster

Download

[C45] Nkie - Interaction Between Race and Insurance Coverage for Gastroenteropancreatic Neuroendocrine Tumor Outcomes

Published in 2024 Listed under Clinical

Download

[C45] Lau - Grade progression in gastrointestinal neuroendocrine tumors

Published in 2023 Listed under Clinical

Download

[C44] Shi - Incidence and prognostic analysis of neuroendocrine differentiation in CRC, GC, ESCC and BTC cohorts

Published in 2024 Listed under Clinical

Download

[C44] Bell - Real-Time Prospective DAXX/ATRX Testing of 186 Consecutive Surgically Resected Pancreatic Neuroendocrine Tumors Reveals Loss of Expression Correlates with Distant Metastasis

Published in 2023 Listed under Clinical

Download

[C43] Zhang - Accuracy of DOTATATE PET Imaging in the Preoperative Planning of Small Bowel Neuroendocrine Tumor Resection

Published in 2023 Listed under Clinical

Download

[C43] Wornow - To Treat or Not to Treat: Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting

Published in 2024 Listed under Clinical

Download

[C43] Poster - Wornow - To Treat or Not to Treat: Resection of Primary Pancreatic Neuroendocrine Tumors in the Metastatic Setting

Published in 2024 Listed under Clinical, Poster

Download

[C43] Lui - Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

Published in 2022 Listed under Clinical

Download

[C42] Poster - Evans - Loss of MGMT Protein Expression by Immunohistochemistry is Associated with Response to Capecitabine/Temozolomide in Neuroendocrine Neoplasms (NENs)

Published in 2024 Listed under Clinical, Poster

Download

[C42] Pai - Small Intestinal NET Recurrence – When Why and How?

Published in 2022 Listed under Clinical

Download

[C42] Luca - Treatment with Lutetium in a real-world setting: How does it affect patient experience and their time-toxicity?

Published in 2023 Listed under Clinical

Download

[C42] Evans - Loss of MGMT protein expression by immunohistochemistry is associated with response to capecitabine/temozolomide in neuroendocrine neoplasms (NENs)

Published in 2024 Listed under Clinical

Download

[C41] Yogo - Long-term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors

Published in 2024 Listed under Clinical

Download

[C41] Pritzl - Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

Published in 2023 Listed under Clinical

Download

[C41] Poster - Yogo - Long-term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors

Published in 2024 Listed under Clinical, Poster

Download

[C41] Chauhan - SSTR-2 Expression in Solid Tumors: An Immunohistochemistry Analysis

Published in 2022 Listed under Clinical

Download

[C40] Winters - Implementation of dosimetry in clinical Lu177-DOTATATE therapy

Published in 2024 Listed under Clinical

Download

[C40] Joseph - TP53 Mutation Portends a Worse Overall Survival in Patients with Advanced Grade 3 Well-Differentiated Neuroendocrine Tumors

Published in 2022 Listed under Clinical

Download

[C40] Grewal - Evaluation of long-term hepatic adverse events in patients receiving Peptide Receptor Radionuclide Therapy (PRRT) following BLAND embolization

Published in 2023 Listed under Clinical

Download

[C3] Vasconcelos - Real-World Evidence of Lenvatinib Use for Treatment of Metastatic Neuroendocrine Neoplasms

Published in 2023 Listed under Clinical

Download

[C3] Uberroth - Prolonged Response to Dabrafenib/Trametinib in Metastatic Well-Differentiated Grade 3 Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation

Published in 2024 Listed under Clinical

Download

[C39] Winters - Dosimetry-guided 131I-mIBG Therapy in a Hemodialysis- Dependent Paraganglioma Patient

Published in 2024 Listed under Clinical

Download

[C39] McElroy - Have We Accounted for Asians? A Critical Analysis of Racial Cancer Disparity Amongst Asian Pancreatic Neuroendocrine Tumor Patients

Published in 2022 Listed under Clinical

Download

[C39] Grewal - Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Neoplasms: A NET Center of Excellence Experience

Published in 2023 Listed under Clinical

Download

[C38] Schnell - Radioactivity in drained body cavity fluid following peptide receptor radionuclide therapy with 177Lu DOTATATE in patients with advanced neuroendocrine tumors

Published in 2024 Listed under Clinical

Download

[C38] Poster - Schnell - Radioactivity in drained body cavity fluid following peptide receptor radionuclide therapy with 177Lu DOTATATE in patients with advanced neuroendocrine tumors

Published in 2024 Listed under Clinical, Poster

Download

[C38] Gupta - Are there any clinical factors associated with PRRTrefractoriness in NET patients?

Published in 2023 Listed under Clinical

Download

[C38] Concors - Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

Published in 2022 Listed under Clinical

Download

[C37] Wahl - Preliminary safety and efficacy data of [212Pb]VMT- α -NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

Published in 2024 Listed under Clinical

Download

[C37] Remick - Initial Experience Using 0.55T MRI for Detection of Liver Metastases in NET Patients

Published in 2023 Listed under Clinical

Download

[C37] Borbon - Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?

Published in 2022 Listed under Clinical

Download

[C36] Pletcher -vUtility of 68Ga-DOTATATE for Grade 3, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Published in 2023 Listed under Clinical

Download

[C36] Patel - Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Thymic Neuroendocrine Neoplasms: A Single-Institutional Case Series

Published in 2024 Listed under Clinical

Download

[C35] Wong - Institutional Retrospective Review of Peptide Receptor Radionuclide Therapy Use in Metastatic Paragangliomas and Pheochromocytomas

Published in 2023 Listed under Clinical

Download

[C35] Poster - Jacques - Small bowel obstruction incidence in Lu177 PRRT patients had no impact on overall survival

Published in 2024 Listed under Clinical, Poster

Download

[C35] Limbach - Liver Directed Therapy is Associated with Improved Survival in Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms with Concurrent Bone Metastasis

Published in 2022 Listed under Clinical

Download

[C35] Jacques - Small bowel obstruction incidence in Lu177 PRRT patients had no impact on overall survival

Published in 2024 Listed under Clinical

Download

[C34] Zaidi - Comparative Assessment of 111In-Octreotide Scintigraphy, 68Ga-DOTATOC PET/CT and 18F-FDG PET/ CT in the Staging and Management of Neuroendocrine Tumors (NETs)

Published in 2023 Listed under Clinical

Download

[C34] Tuchayi - Peptide Receptor Radionuclide Therapy with 177 Lu- DOTATATE: A Single Center Experience

Published in 2024 Listed under Clinical

Download

[C34] Poster - Tuchayi - Peptide Receptor Radionuclide Therapy with 177 Lu - DOTATATE: A Single Center Experience

Published in 2024 Listed under Clinical, Poster

Download

[C33] Salem - DOTATATE PET/CT Imaging In Prostate Cancer: Incidental Observations and Potential Future Implications

Published in 2023 Listed under Clinical

Download

[C33] Cass - Corticosteroid prophylaxis did not decrease tumor flare reaction in high-risk neuroendocrine tumors patients treated with 177Lu-DOTATATE

Published in 2024 Listed under Clinical

Download

[C32] Ziogas - Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Published in 2022 Listed under Clinical

Download

[C32] Trikalinos - Myelodysplasia and leukemia instances after PRRT: Experience from a tertiary institution

Published in 2023 Listed under Clinical

Download

[C32] Bilgin - Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Malignant Pheochromocytoma (PCC) and Paraganglioma (PGL): A Single Institution Retrospective Study

Published in 2024 Listed under Clinical

Download

[C31] Singh - First-Line Efficacy of [177Lu]Lu-DOTA-TATE in Gastroenteropancreatic Neuroendocrine Tumors by Tumor Grade and Primary Origin: Phase 3 NETTER-2 Subgroup Analysis

Published in 2024 Listed under Clinical

Download

[C31] Patel - Goblet Cell Adenocarcinoma (GCA) of the Appendix: Interrogating Proteomics to Identify Potential Actionable Targets

Published in 2022 Listed under Clinical

Download

[C31] Al-Ward - High-Specific-Activity Iodine-131-Meta-Iodo- Benzylguanidine for the Treatment of Advanced Pheochromocytoma and Paraganglioma: A Real-World Study

Published in 2023 Listed under Clinical

Download

[C30] Meloche-Dumas - Liver-Directed Therapy of Neuroendocrine Liver Metastases

Published in 2022 Listed under Clinical

Download

[C30] Maratta - Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: A comprehensive analysis of expression in the era of somatostatin receptor PET imaging

Published in 2024 Listed under Clinical

Download

[C30] Lareef - Novel Alternate (Alt) Response Criteria for early outcome prediction in Pancreatic (P) Neuroendocrine Tumors (NETs): Utilizing banked imaging and radiomics

Published in 2023 Listed under Clinical

Download

[C2] Urrego - Neuroendocrine tumor metastatic to breast: case report and review of the literature

Published in 2023 Listed under Clinical

Download

[C2] Sun - Preliminary clinical activity of surufatinib combined with octreotide LAR in patients with G1/2 gastroenteropancreatic neuroendocrine tumor (GEP-NET)

Published in 2024 Listed under Clinical

Download

[C2] Hunter - Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Neoplasms

Published in 2022 Listed under Clinical

Download

[C29] Poster - D'Souza - Integrating Yttrium - 90 Radioembolization with Capecitabine - Temozolomide for Grade 3 Liver - Dominant Metastatic Neuroendocrine Tumors: Initial Outcomes

Published in 2024 Listed under Clinical, Poster

Download

[C29] Pelle - Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate

Published in 2023 Listed under Clinical

Download

[C29] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI the Detection of VHL-related Pheochromocytoma

Published in 2022 Listed under Clinical

Download

[C29] D'Souza - Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors

Published in 2024 Listed under Clinical

Download

[C28] Zhou - Liver-directed therapy for metastatic neuroendocrine carcinoma and grade 3 well-differentiated neuroendocrine tumors

Published in 2024 Listed under Clinical

Download

[C28] Poster - Zhou - Liver - directed therapy for metastatic neuroendocrine carcinoma and grade 3 well - differentiated neuroendocrine tumors

Published in 2024 Listed under Clinical, Poster

Download

[C28] Jha - Diagnostic Performance of PET or PET/CT Utilizing 18F-DOPA, 68Ga-DOTATATE, 18F-FDG, 18F-FDA, and CT and MRI in the Detection of MEN2A-relatedpheochromocytoma

Published in 2022 Listed under Clinical

Download
  • «
  • 1
  • 2
  • 3
  • …
  • 6
  • 7
  • »

NANETS

167 Madison Avenue, Suite 205, #646 | New York, NY 10016
(718) 283-4783 | staff@nanets.net

Member Login

Twitter Facebook LinkedIn
  • Privacy Policy
  • |
  • Site Map

Copyright ©2026 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG.
ADG is a certified Women Owned Business.